Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone for dominant optic atrophy
ACTRN12621000826842Phase 2Not yet recruiting
- Sponsor
- Northern Sydney Local Health District
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dominant optic atrophy (DOA) comparing Idebenone with Placebo (2 arms). Primary endpoint: Change from baseline in best-corrected visual acuity in the best eye. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
idebenone
03
Conditions
dominant optic atrophy (DOA)
Beyond the preview
Go deeper on ACTRN12621000826842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000826842.